Lightweight opinion information direction = correct – superficial seeking public acceptance – not science
…”mRNA vaccines have many benefits. They are quick to design, so once the manufacturing platform is set up, mRNA vaccines can be designed to target viruses, or variants, very quickly. The vaccine manufacturing is also fully synthetic, and doesn’t rely on living cells like chicken eggs, or cultured cell lines….” read more…
Questions over downstream health impacts.
‘Ordinarily, two months is way shorter than it would normally take to assess phase 3 trial results,’ he said.
‘But no one’s going to be happy if we say, “Yeah, we’ll get a vaccine to you in five years”. So it’s a risk–benefit analysis…..”‘Now, of course, none of this will tell you if there’s going to be a problem that might crop up a year later, and there’s no way around that other than wait for a year or two years or five years or however long any longer term potential problems might take…”
According to Dr Marks, safety is what ‘keeps [him] up at night’.
‘The way we’re going to get over COVID-19 is if we get a vaccine that has 70% or 80% efficacy and we can deploy that to 70 or 80% of the population,’ he said.
‘[That way] we actually have a chance of having herd immunity, and we can be back in restaurants and in banks … and doing what we normally do.
‘[But] it’s only going to happen if people have confidence enough to go get vaccinated, and we do have a crisis in vaccine confidence.’
University of Sydney vaccine expert Professor Robert Booy told newsGP ‘past experience’ suggests a vaccine candidate is unlikely to produce a serious side effect beyond about two months….
(Steve) this is the very same risk assessment offered up via Ipi/Nivo and keytruda – recent findings in trial cohorts of >200 patients showed 48% of patients did not develop downstream thyroid dysfunctions/lesions at 18 months – but observed that the more successful performing patients did develop downstream impacts – most probably due to overgrowth from amplifications to induce a larger immune response – also separately – replicon mRNA are 3 times larger than native mRNA.
Professor Booy said he is not ‘massively concerned’ about the safety of the two mRNA candidates, but does still hold some reservations.
‘I’m still a bit nervous about mRNA because it’s so new – and it’s so new that we can’t even speculate what it’s going to cause,’ he said.
‘That’s why I suggest the best quality phase 4 post-marketing surveillance, with follow-up at three months after vaccination and six months. Then you’ll have the kind of quality reassurance to go on with the program.’
‘There are chronic effects as well, in a minority of people, and again, it can affect the heart, the lungs, the brain and the kidneys in a chronic way.
‘I don’t want either of those downsides.’